DRIP Score for Drug-Resistant Pneumonia
Drug Resistance in Pneumonia (DRIP) score. Predicts risk of drug-resistant pneumonia pathogens to guide empirical antibiotic selection in CAP and HCAP patients.
Score interpretation
→ DRIP High Risk (≥4): High probability of drug-resistant pathogens (MRSA, Pseudomonas, MDR gram-negatives). Broad-spectrum antibiotics: add anti-MRSA agent (vancomycin/linezolid) AND anti-pseudomonal agent (piperacillin-tazobactam). Cultures before antibiotics; de-escalate per results.
→ DRIP Low Risk (0–3): Drug-resistant pathogens unlikely. Standard CAP antibiotics appropriate: beta-lactam + macrolide OR respiratory fluoroquinolone. No need for broad-spectrum cover.
Interpretation bands for the DRIP Score. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Pneumonia Severity Index (PSI/PORT) · Pneumonia
- CRB-65 Score for Community Pneumonia · Pneumonia
- SMART-COP Score for Pneumonia Severity · Pneumonia
- CURB-65 Score for Community-Acquired Pneumonia · Pneumonia
- MuLBSTA Score for Viral Pneumonia Mortality · Pneumonia
- DRIP Score for Drug-Resistant Pneumonia · Pneumonia
- Linezolid · Oxazolidinone — MRSA / VRE / Drug-Resistant TB (adjunct)
- Linezolid (Burns — Vancomycin-Resistant/Refractory MRSA) · Antibiotic — Oxazolidinone
- Flucloxacillin · Antibiotic — Penicillinase-Resistant
- Flucloxacillin · Antibiotic (Penicillinase-Resistant Penicillin)
- Teicoplanin · Glycopeptide Antibiotic — MRSA / Gram-Positive Infections
- Amikacin · Aminoglycoside — Drug-Resistant Gram-Negative / MDR-TB
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.